tetano
Editor, Senior Moderator
Int J Antimicrob Agents. 2016 Jun 8. pii: S0924-8579(16)30123-6. doi: 10.1016/j.ijantimicag.2016.05.003. [Epub ahead of print]
[h=1]Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections.[/h] Lee N[SUP]1[/SUP], Chan PK[SUP]2[/SUP], Tam WW[SUP]3[/SUP], Chan MC[SUP]4[/SUP], Lui GC[SUP]5[/SUP], Kwok AK[SUP]4[/SUP], Ko FW[SUP]5[/SUP], Ng SS[SUP]5[/SUP], Yung IM[SUP]5[/SUP], Wong RY[SUP]5[/SUP], Hui DS[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] An open-label trial on intravenous peramivir was conducted among adult patients hospitalised for influenza-associated lower respiratory tract complications (LRTCs). Virus culture and quantitative reverse transcription PCR (qRT-PCR) were performed serially until Day 10. Peramivir treatment was associated with viral RNA decline as well as culture and RNA negativity, which occurred at rates comparable with those of oseltamivir: by Day 5, viral load decline -2.5 log[SUB]10[/SUB] copies/mL [β[SUB]interaction[/SUB] -0.071, standard error (SE) 0.121, 95% confidence interval (CI) -0.309 to 0.167]; culture-negative, 94% (vs. 95%); and RNA-negative, 44% (vs. 36%). Extended treatment of >5 days was required in 69% of cases because of slow clinical resolution and viral clearance in LRTCs. Peramivir was well tolerated. These data are useful for future trial design in this unique population.
Copyright ? 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
[h=4]KEYWORDS:[/h] Influenza; Lower respiratory tract complications; Peramivir
PMID: 27319273 [PubMed - as supplied by publisher]
[h=1]Virological response to peramivir treatment in adults hospitalised for influenza-associated lower respiratory tract infections.[/h] Lee N[SUP]1[/SUP], Chan PK[SUP]2[/SUP], Tam WW[SUP]3[/SUP], Chan MC[SUP]4[/SUP], Lui GC[SUP]5[/SUP], Kwok AK[SUP]4[/SUP], Ko FW[SUP]5[/SUP], Ng SS[SUP]5[/SUP], Yung IM[SUP]5[/SUP], Wong RY[SUP]5[/SUP], Hui DS[SUP]6[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] An open-label trial on intravenous peramivir was conducted among adult patients hospitalised for influenza-associated lower respiratory tract complications (LRTCs). Virus culture and quantitative reverse transcription PCR (qRT-PCR) were performed serially until Day 10. Peramivir treatment was associated with viral RNA decline as well as culture and RNA negativity, which occurred at rates comparable with those of oseltamivir: by Day 5, viral load decline -2.5 log[SUB]10[/SUB] copies/mL [β[SUB]interaction[/SUB] -0.071, standard error (SE) 0.121, 95% confidence interval (CI) -0.309 to 0.167]; culture-negative, 94% (vs. 95%); and RNA-negative, 44% (vs. 36%). Extended treatment of >5 days was required in 69% of cases because of slow clinical resolution and viral clearance in LRTCs. Peramivir was well tolerated. These data are useful for future trial design in this unique population.
Copyright ? 2016 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
[h=4]KEYWORDS:[/h] Influenza; Lower respiratory tract complications; Peramivir
PMID: 27319273 [PubMed - as supplied by publisher]